Extended indication Gastric cancer
Therapeutic value No judgement
Total cost 27,750,000.00
Registration phase Withdrawn

Product

Active substance Atezolizumab
Domain Oncology and Hematology
Reason of inclusion Indication extension
Main indication Stomach cancer
Extended indication Gastric cancer
Proprietary name Tecentriq
Manufacturer Roche
Mechanism of action PD-1 / PD-L1 inhibitor
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional comments An engineered anti-PD-L1 antibody

Registration

Registration route Centralised (EMA)
Orphan drug No
Registration phase Withdrawn
Additional comments Roche geeft aan dat deze indicatie-uitbreiding niet meer wordt verwacht.

Therapeutic value

Therapeutic value No judgement
Substantiation Momenteel zijn fase II studies gaande.

Expected patient volume per year

Patient volume

< 555

Market share is generally not included unless otherwise stated.

References NKR
Additional comments In 2016 waren er gemiddeld 555 nieuwe patiënten met cardia of non-cardia maagadenocarcinoom stadium IV.

Expected cost per patient per year

Cost 40,000.00 - 60,000.00
References Medicijnkosten.nl; drugs.com
Additional comments Verwacht in lijn met andere immunotherapieën. €1098,16 voor nivolumab 10mg per ml fl 10 ml; €3355,96 voor pembrolizumab 25 mg per ml fl 4ml. In de VS $9.000 dollar voor 1200 mg 20 ml. Voor alle indicaties van atezolizumab geldt een financieel arrangement die is voortgekomen uit de onderhandelingen in de sluis (lopend tot en met 31 december 2019). Voor de indicatie blaaskanker zit atezolizumab nog in de sluis.

Potential total cost per year

Total cost

27,750,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Er lopen meerdere PhIII studies.

Other information

There is currently no futher information available.